| Robert J. de Luccia |
Robert J. de Luccia founded Dipexium Pharmaceuticals, Inc. in 2010, where he worked as Executive Chairman from 2014 to 2017 and Acurx Pharmaceuticals, Inc. in 2017, where he is working as Executive Chairman from 2017. Mr. de Luccia also currently works at IBEX Technologies, Inc., as Lead Independent Director from 2012. Mr. de Luccia also formerly worked at Immunomedics, Inc., as President & Chief Executive Officer from 1998 to 1999, MacroChem Corp., as Chairman, President & Chief Executive Officer from 2004 to 2009, Morris Plains Property LLC, as Chief Executive Officer, Topigen Pharmaceuticals, Inc., as Director, Pfizer Inc., as Vice President-Marketing & Sales Operations, Sanofi Winthrop, as President, Sterling Winthrop, Inc., as President, and Sanofi-Aventis U.S. LLC, as President. Mr. de Luccia received his undergraduate degree and Masters Business Admin degree from Iona College. |
| Michael Silverman |
Michael Silverman currently works at Acurx Pharmaceuticals, Inc., as Medical Director, Luckwel Pharmaceuticals, Inc., as Chief Medical Officer, and The Massachusetts Medical Society, as Member. Dr. Silverman received his graduate degree from Pritzker School of Medicine. |
| Robert G. Shawah |
Robert G. Shawah is the founder of Acurx Pharmaceuticals, Inc. (founded in 2017) and holds the title of Chief Financial Officer. He also held the position of Director at Ameri100 Holdco, Inc. in 2018. Prior to that, he served as Treasurer & Chief Accounting Officer at Dipexium Pharmaceuticals, Inc. from 2014 to 2017. Additionally, he was Vice President & Partner at Baldwin Pearson & Co., Inc. in 2013. Mr. Shawah obtained his undergraduate degree from Bucknell University. |
| David P. Luci |
David P. Luci was the founder of Dipexium Pharmaceuticals, Inc. (founded in 2010) where he served as President, CEO, Secretary & Director from 2010 to 2017. He is also the founder of Acurx Pharmaceuticals, Inc. (founded in 2017) where he currently holds the position of President, CEO, Secretary & Director. Mr. Luci's current job(s) include being the Chairman of Digital Prime Technologies since 2019 and a Member of the New York State Bar Association. In the past, Mr. Luci held positions as President & Director at MacroChem Corp. from 2007 to 2009, Director at Abeona Therapeutics, Inc. from 2009 to 2010, Director at Ameri Holdings, Inc. from 2018 to 2019, and Corporate Associate at Paul, Hastings, Janofsky & Walker LLP from 1994 to 2002. He also served as CFO, Secretary, Executive VP & General Counsel at Bioenvision, Inc. from 2002 to 2007. Additionally, he worked as a Senior Auditor at Ernst & Young LLP. Mr. Luci's education includes an undergraduate degree from Bucknell University and a graduate degree from Albany Law School. |
| Jack Hugh Dean |
Jack Hugh Dean was the founder of Dipexium Pharmaceuticals, Inc. (founded in 2010) and held the title of Director from 2010 to 2014. He is currently working as a Director at ReSearch Pharmaceutical Services LLC since 2008, as an Independent Director at Acurx Pharmaceuticals, Inc. since 2021, as the President of Drug Development Advisors LLC since 2006, as a Trustee at ILSI Health & Environmental Sciences Institute since 1994, and as a Professor at the University of Arizona College of Pharmacy since 2006. In his former positions, Dr. Dean worked as the Global Director-Preclinical Development at Sanofi from 1988 to 2006, as a Director at Sanofi-Synthelabo, Inc., as the Director of Sterling Winthrop Pharmaceuticals Research Center from 1990 to 1992, as the Director-Department of Immunology at Litton Bionetics, Inc. from 1975 to 1979, as the Vice President-Drug Safety at Sterling Winthrop, Inc. from 1989 to 1992, as the Head-National Toxicology Program at the National Institutes of Health from 1982 to 1988, as the President-US Science & Medical Affairs at Sanofi-Aventis U.S. LLC from 1988 to 2006, as the Head-Immunotoxicology Section at The National Institute of Environmental Health Sciences from 1982 to 1988, and as the Head-Cellular & Molecular Toxicology Department at The Hamner Institutes for Health Sciences from 1982 to 1988. Dr. Dean's education includes undergraduate and graduate degrees from The California State University and a doctorate degree from the University of Arizona College of Medicine (conferred in 1972). |
| Carl V. Sailer |
Carl V. Sailer is an Independent Director at Acurx Pharmaceuticals, Inc. and Vice President-Global Client Solutions at Syneos Health, Inc. He was previously Vice President-Sales & Marketing at Emisphere Technologies, Inc., Vice President-Product Commercialization at Interpace Biosciences, Inc., Vice President-Commercial Operations at Akrimax Pharmaceuticals LLC, and Vice President-Product Commercialization at New American Therapeutics, Inc. Sailer holds an MBA from Hofstra University and an undergraduate degree from Seton Hall University. |
| Thomas L. Harrison |
Thomas L. Harrison founded Harrison & Star Business Group in 1992, where he worked as Chairman from 1992 to 1997. Dr. Harrison also currently works at MediaJel, Inc., as Chairman from 2019, Actv8, Inc., as Director from 2021, GL Brands, Inc., as Director from 2020, The New York Academy of Medicine, as Director, The Children’s Hospital at Montefiore, as Director, Madison Logic, Inc., as Director from 2017, Magellan Jets LLC, as Director, Tek Array, Inc., as Director, Frontier Financial Group, Inc., as Director, Acurx Pharmaceuticals, Inc., as Independent Director from 2021, MainStem, Inc., as Director, Cheech & Chongs Cannabis Co., as Independent Director from 2020, AFC Gamma, Inc., as Lead Independent Director from 2020, Montefiore Medical Center, as Trustee, and Kent School Corp., as Trustee. Dr. Harrison also formerly worked at DAS Holdings, Inc., as Chairman & Chief Executive Officer from 1998 to 2013, Omnicom Group, Inc., as Chairman-Diversified Healthcare Communications from 1992 to 1997, Das Group of Cos, as Chairman-Emeritus, Epocrates LLC, as Independent Director from 2011 to 2013, Zynerba Pharmaceuticals, Inc., as Independent Director from 2015 to 2019, rVue Holdings, Inc., as Director, Social Growth Technologies, Inc., as Director from 2014 to 2016, Dipexium Pharmaceuticals, Inc., as Independent Director & Partner from 2014 to 2017, Morgans Hotel Group Co., as Independent Director from 2011 to 2013, Caladrius Biosciences, Inc., as Director, The Arthritis Foundation, as Director, Lymphoma Research Foundation, as Director, rVue, Inc., as Director from 2013 to 2016, Fifth Street Asset Management, Inc., as Lead Independent Director, New York Academy of Sciences, as Member-Governors Board, and Merida Capital Holdings LLC, as Senior Operating Partner. Dr. Harrison received his undergraduate degree from Shepherd University (West Virginia) and graduate degree in 1972 from West Virginia University. |
| Joseph C. Scodari |
Joseph C. Scodari currently works at Janssen, Inc., as Group Chairman, OptiNose US, Inc., as Chairman from 2017, Acurx Pharmaceuticals, Inc., as Independent Director from 2021, and Rutgers Robert Wood Johnson Medical School, as Member-Overseers Board. Mr. Scodari also formerly worked at Johnson & Johnson, as Chairman-Worldwide Pharmaceuticals Group from 2005 to 2008, Biotechnology Innovation Organization, as Vice Chairman from 2003 to 2008, OptiNose, Inc., as Independent Chairman from 2017 to 2023, Ortho-McNeil Pharmaceutical LLC, as Group Chairman, Life Sciences Pennsylvania, as Chairman, Janssen Pharmaceutica NV, as Group Chairman, Pharmacyclics LLC, as Director, Labcorp Drug Development, Inc., as Independent Director from 2009 to 2015, Endo Health Solutions, Inc., as Independent Director from 2011 to 2013, Actelion Ltd., as Director from 2009 to 2011, Endo Pharmaceuticals, Inc., as Director, the University of the Sciences in Philadelphia, as Director, National Pharmaceutical Council, as Director, Actelion Pharmaceuticals Ltd., as Director, Centocor, Inc., as President & Chief Operating Officer from 1998 to 1999, Northwest Regional Development Agency, as Associate Member, Sterling Drug, Inc., as Vice President-Strategic Marketing, Rhone Poulenc Rorer, as Vice President-Marketing & Business Development, and Gwynedd-Mercy College, as Trustee. Mr. Scodari received his undergraduate degree from Youngstown State University. |
| James J. Donohue |
James J. Donohue is an Independent Director at Acurx Pharmaceuticals, Inc. and a Vice President at CRA International, Inc. He obtained an undergraduate degree from Villanova University. |
